ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Medicenna Therapeutics Corporation (QB)

Medicenna Therapeutics Corporation (QB) (MDNAF)

1.43
0.02
(1.42%)
Closed July 23 4:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.43
Bid
1.31
Ask
1.60
Volume
21,489
1.35 Day's Range 1.43
0.158 52 Week Range 2.20
Market Cap
Previous Close
1.41
Open
1.35
Last Trade
500
@
1.43
Last Trade Time
Financial Volume
$ 30,327
VWAP
1.4113
Average Volume (3m)
110,901
Shares Outstanding
76,182,036
Dividend Yield
-
PE Ratio
-5.83
Earnings Per Share (EPS)
-0.33
Revenue
-
Net Profit
-25.47M

About Medicenna Therapeutics Corporation (QB)

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Toronto, Ontario, Can
Founded
1970
Medicenna Therapeutics Corporation (QB) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QB) was $1.41. Over the last year, Medicenna Therapeutics (QB) shares have traded in a share price range of $ 0.158 to $ 2.20.

Medicenna Therapeutics (QB) currently has 76,182,036 shares outstanding. The market capitalization of Medicenna Therapeutics (QB) is $107.42 million. Medicenna Therapeutics (QB) has a price to earnings ratio (PE ratio) of -5.83.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.12-7.741935483871.551.681.35784831.47928009CS
40.021.418439716311.411.681.33666291.46836092CS
12-0.43-23.11827956991.862.21.21109011.71533387CS
261.098330.7228915660.3322.20.3031207061.32886236CS
521.266771.9512195120.1642.20.1581145351.06870345CS
1561.266771.9512195120.1642.20.1581145351.06870345CS
2600.352432.70230141051.07765.320.158798151.7561263CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
LGCBLinkage Global Inc
$ 3.6601
(-29.82%)
168k
CGBSCrown LNG Holdings Ltd
$ 0.9997
(-29.10%)
3.39M
SPECSpectaire Holdings Inc
$ 0.3962
(-24.53%)
1.87M
GSUNGolden Sun Health Technology Group Ltd
$ 5.13
(-23.66%)
158.79k
PSNLPersonalis Inc
$ 2.9808
(-22.58%)
3.11M
NVDANVIDIA Corporation
$ 123.54
(4.76%)
239M
SQQQProShares UltraPro Short QQQ
$ 8.09
(-4.37%)
183.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
SERVServe Robotics Inc
$ 8.73
(15.63%)
151.56M
NCPLNetcapital Inc
$ 0.1118
(7.50%)
124.37M

MDNAF Discussion

View Posts
2H2 2H2 2 months ago
And more awesome results. 20x bagger here soon? Pc needs a new top line therapy, guess who?
πŸ‘οΈ0
2H2 2H2 3 months ago
MDNAF is a presenter at ASCO. Huge news!
πŸ‘οΈ0
2H2 2H2 3 months ago
Great presentation at ASCO
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
πŸ‘οΈ0
2H2 2H2 5 months ago
Relishing soon. This will be 10x current value this year
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
πŸ‘οΈ0
2H2 2H2 5 months ago
Getting legs here. Train leaving.
πŸ‘οΈ0
axelvento axelvento 8 months ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
πŸ‘οΈ0
Renee Renee 9 months ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
MDNA NEW 52 week low
πŸ‘οΈ0
Investopotia Investopotia 2 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
πŸ‘οΈ0
EagleD EagleD 4 years ago
Going much higher. Double digits in a few months
πŸ‘οΈ0
EagleD EagleD 4 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
πŸ‘οΈ0
EagleD EagleD 4 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
πŸ‘οΈ0
EagleD EagleD 4 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
πŸ‘οΈ0
Renee Renee 4 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
πŸ‘οΈ0
tykundegex tykundegex 6 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
πŸ‘οΈ0
BioSpecialist BioSpecialist 7 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
πŸ‘οΈ0